Skip to main content
Deciphera
  • Our Company
    • Who We Are
    • Leadership
  • Focus Areas
    • Overview
    • Oncology
    • Immunology & Inflammation
    • Neurology
  • Pipeline
    • Ongoing Clinical Trials
    • Presentations & Publications
  • Patients & Care Partners
    • Expanded Access
  • Healthcare Professionals (Coming soon!)
  • Our Medicines
  • Join Us
    • Our Culture
    • Open Positions
  • News
May 13, 2025
Vimseltinib
ISPOR 2025

Characterizing Improvements in Physical Functioning with PROMIS-PF and In-trial Exit Interviews: A Mixed-methods Analysis to Understand the Meaningful Changes Experienced by Patients on Vimseltinib in the MOTION Trial

Subscribe to ISPOR 2025

© 2026 Deciphera. All Rights Reserved.

  • Privacy Policy
  • Contact Us
  • Terms of Use
linkedin twitter
Back to top